UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.) 1

Repare Therapeutics Inc.
(Name of Issuer)
Common Shares, no par value
(Title of Class of Securities)
760273102
(CUSIP Number)
June 19, 2020
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act

(however, see the Notes).

			
1	NAME OF REPOR	TING PERSON	
		y Value Fund, L.P.	
2	CHECK THE APPI	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES		SOLE VOING FOWER	
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH		SHAKED VOINGTOWEK	
REPORTING		988,610	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
PERSON WITH	/	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		222 242	
		988,610	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	988,610		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.7%		
12	TYPE OF REPORT	TING PERSON	
	PN		
ļ <u> </u>			

1	NAME OF DEDOL	OTING DEDCON	
1	NAME OF REPORTING PERSON		
	BVF I GP LI	C	
2			(-) [7]
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
			(0) □
3	SEC USE ONLY		
3	SEC USE ONLI		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH		000 C10	
REPORTING PERSON WITH	7	988,610 SOLE DISPOSITIVE POWER	
PERSON WITH	/	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	·
		OTHER PROPERTY OF THE PROPERTY	
		988,610	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	-
	988,610		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCEME OF CL	ACC DEDDECEMTED DV AMOUNT IN DOM (0)	
11	PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.7%		
12	TYPE OF REPORT	TING PERSON	
	00		

1	NAME OF REPO	ORTING PERSON	
		ogy Value Fund II, L.P.	
2	CHECK THE AP	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP O	R PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		769,195	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
	1.000000000	769,195	
9	AGGREGATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	ECO 105		
10	769,195	THE ACCRECATE AMOUNT IN DOLL (I) EVOLUTING CERTAIN CHARGE	
10	CHECK BOX IF	THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DED CENTE OF C	ACC DEDDECEMBED DV AMOUNT IN DOW (0)	
11	PERCENT OF C	LASS REPRESENTED BY AMOUNT IN ROW (9)	
	2.1%		
12	TYPE OF REPOR	OTING DEDGON	
12	I YPE OF KEPOI	KIING PEKSUN	
	DN		
	PN		

1	NAME OF REPORT	TING DEPSON	
1	NAME OF REPORT	TING LERSON	
	BVF II GP LI	.C	
2	CHECK THE APPR	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) □
3	SEC USE ONLY		
4	CITIZENSHID OR 1	PLACE OF ORGANIZATION	
4	CITIZENSIIII OK	LAGE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		769,195	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		769,195	
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
J	AGGILEZILI TIMI	SONT BENEFICINEET OWNED BY ENGINEET ON THE ON THE	
	769,195		
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
11	FERCENT OF CLA	33 REFRESENTED DT AMOUNT IN ROW (9)	
	2.1%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF REPORT	TINC DEDCON	
1	NAME OF REPORT	ING PERSON	
	Riotechnology	Value Trading Fund OS LP	
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
2	CHECK THE AFFIX	OFRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠ (b) □
			(6) 🗆
3	SEC USE ONLY		
_			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Cayman Island		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		135,693	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
TERSON WITH	/	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		135,693	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	135,693		
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
11	PERCENT OF CLA	33 REFRESENTED DY AMIDUNT IN ROW (9)	
	Less than 1%		
12	TYPE OF REPORT	ING PERSON	
	PN		

			
1	NAME OF REPOR	TING PERSON	
	BVF Partners		
2	CHECK THE APPI	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	Cayman Islan	ds	
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		135,693	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		135,693	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	135,693		
10	CHECK BOX IF TI	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
	Less than 1%		
12	TYPE OF REPORT	TING PERSON	
	CO		

1	NAME OF REPORT	TING PERSON	
1	NAME OF REPORT	ING LEASON	
	BVF GP HOL	DINGS LLC	
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵
			(b) 🗆
3	SEC USE ONLY		
4	CITIZENSHID OR I	PLACE OF ORGANIZATION	
4	CITIZENSIIII OKI	EAGE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING		1,757,805	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		1 757 905	
9	AGGREGATE AMO	1,757,805 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
J	AGGILEZITE AIVIC	DENTE TO THE OWNER OF THE OWNER	
	1,757,805		
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
11	FERCENT OF CLA	33 REFRESENTED DT AMOUNT IN ROW (3)	
	4.8%		
12	TYPE OF REPORT	ING PERSON	
	00		

1	NAME OF REPORT	TING PERSON		
1	THE OF REPORT			
	BVF Partners	L.P.		
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠	
			(b) □	
	CEC LICE ONLY			
3	SEC USE ONLY			
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION		
	_			
NUMBER OF	Delaware	COLE MOTING POLITER		
NUMBER OF SHARES	5	SOLE VOTING POWER		
BENEFICIALLY		0 shares		
OWNED BY	6	SHARED VOTING POWER		
EACH				
REPORTING PERSON WITH		1,944,546		
PERSON WITH	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
0	ACCDECATE AMO	1,944,546 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
9	AGGREGALE AMO	JUNI BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,944,546			
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	DEDCENT OF CLA	CC DEDDECENTED DV A MOLINIT IN DOM (0)		
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)		
	5.3%			
12	TYPE OF REPORT	ING PERSON		
	DNI 14			
	PN, IA			

1	NAME OF REPORT	TINC DEDCON	
1	NAME OF REPORT	ING PERSON	
	BVF Inc.		
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
2	CHECK THE MITK	OTRINIE BOX II A WEWIDER OF A GROOT	(a) ≧ (b) □
			(5)
3	SEC USE ONLY		
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES		01	
BENEFICIALLY OWNED BY	6	0 shares SHARED VOTING POWER	
EACH	0	SHARED VOTING POWER	
REPORTING		1,944,546	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		1,944,546	
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1 044 546		
10	1,944,546	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	П
10	CHECK BOX II' II	LE AGGREGATE AMOUNT IN NOW (9) EXCLUDES CERTAIN STIARES	
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
	5.3%		
12	TYPE OF REPORT	NG PERSON	
	CO		

	T		
1	NAME OF REPOR	TTING PERSON	
	Mark N. Lam		
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠
			(b) □
3	SEC USE ONLY		
4	CITIZENSHIP OR	PLACE OF ORGANIZATION	
	United States		
NUMBER OF	5	SOLE VOTING POWER	
SHARES			
BENEFICIALLY		0 shares	
OWNED BY	6	SHARED VOTING POWER	
EACH			
REPORTING		1,944,546	
PERSON WITH	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		1,944,546	
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,944,546		
10		HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
		()	
11	PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
		(-)	
	5.3%		
12	TYPE OF REPORT	TING PERSON	
	IN		

Item 1(a). Name of Issuer:

Repare Therapeutics Inc., a Canada corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

7210 Frederick-Banting, Suite 100 St-Laurent, Québec, Canada H4S 2A1

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2")

44 Montgomery St., 40th Floor San Francisco, California 94104

Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS")

PO Box 309 Ugland House Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Shares, no par value (the "Shares").

Item 2(e). CUSIP Number:

760273102

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section $3(c)(14)$ of the Investment Company Act.
(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on June 29, 2020, (i) BVF beneficially owned 988,610 Shares, (ii) BVF2 beneficially owned 769,195 Shares and (iii) Trading Fund OS beneficially owned 135,693.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 988,610 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 769,195 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 135,693 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 1,757,805 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 1,944,546 Shares beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and a certain Partners managed account (the "Partners Managed Account"), including 51,048 Shares held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 1,944,546 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 1,944,546 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by BVF2. Partners OS disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 36,668,085 Shares outstanding, as disclosed in the Issuer's Prospectus on Form 424B4 filed with the Securities and Exchange Commission on June 19, 2020.

As of the close of business on June 29, 2020, (i) BVF beneficially owned approximately 2.7% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 2.1% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 2.7% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 2.1% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 4.8% of the outstanding Shares, and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 5.3% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF Inc., BVF2, Trading Fund OS and the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or

Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

BVF Inc., its general partner

/s/ Mark N. Lampert Mark N. Lampert President

By:

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 29, 2020 BIOTECHNOLOGY VALUE FUND, L.P. BIOTECHNOLOGY VALUE TRADING FUND OS LP By: BVF Partners L.P., its investment manager BVF I GP LLC., its general partner BVF Inc., its general partner By: /s/ Mark N. Lampert Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark Lampert President **BVF I GP LLC BVF GP HOLDINGS LLC** /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark Lampert Chief Executive Officer BIOTECHNOLOGY VALUE FUND II, L.P. BVF PARTNERS L.P. BVF II GP LLC, its general partner By: BVF Inc., its general partner /s/ Mark N. Lampert By: Mark N. Lampert /s/ Mark N. Lampert Chief Executive Officer Mark N. Lampert President **BVF II GP LLC** BVF INC. By: /s/ Mark N. Lampert /s/ Mark N. Lampert Mark N. Lampert Chief Executive Officer Mark Lampert President BVF PARTNERS OS LTD. /s/ Mark N. Lampert BVF Partners L.P., its sole member MARK N. LAMPERT

17

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated June 29, 2020 with respect to the shares of Common Shares, no par value, of Repare Therapeutics Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Dated: June 29, 2020

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert
Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark Lampert President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF INC.

By: /s/ Mark N. Lampert

Mark Lampert President

/s/ Mark N. Lampert

MARK N. LAMPERT